Key Points
- Director Jay Kunkel sold 4,510 shares on March 20 at an average of $11.14 for $50,241.40, reducing his position by 16.13% to 23,450 shares (approx. $261,233).
- Varex recently beat estimates, reporting $0.19 EPS vs. $0.14 expected and $209.6M in revenue, and set Q2 2026 guidance of $0.15–$0.25 despite a negative net margin and a market cap near $453M.
- Analyst views and stock metrics are mixed: shares opened at $10.82, trade in a 12‑month range of $6.76–$14.56, and carry an average "Hold" rating with a $16.17 price target (two Buys, one Hold, one Sell).
Varex Imaging (NASDAQ:VREX - Get Free Report) Director Jay Kunkel sold 4,510 shares of the company's stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $11.14, for a total value of $50,241.40. Following the sale, the director owned 23,450 shares of the company's stock, valued at approximately $261,233. This trade represents a 16.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Varex Imaging Stock Up 1.5%
Shares of VREX stock opened at $10.82 on Tuesday. The stock's 50 day simple moving average is $13.06 and its 200 day simple moving average is $12.25. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.87 and a current ratio of 3.89. Varex Imaging has a twelve month low of $6.76 and a twelve month high of $14.56. The company has a market capitalization of $453.36 million, a price-to-earnings ratio of -6.60 and a beta of 0.88.
Varex Imaging (NASDAQ:VREX - Get Free Report) last posted its earnings results on Tuesday, February 10th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.05. Varex Imaging had a positive return on equity of 8.43% and a negative net margin of 7.92%.The firm had revenue of $209.60 million during the quarter, compared to analyst estimates of $207.83 million. Varex Imaging has set its Q2 2026 guidance at 0.150-0.250 EPS. As a group, research analysts predict that Varex Imaging will post 0.53 EPS for the current year.
Analyst Ratings Changes
Several research firms recently issued reports on VREX. Jefferies Financial Group reaffirmed a "hold" rating and set a $14.50 price objective on shares of Varex Imaging in a report on Monday, February 2nd. Wall Street Zen raised shares of Varex Imaging from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 28th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Varex Imaging in a research report on Monday, December 29th. Finally, B. Riley Financial reiterated a "buy" rating on shares of Varex Imaging in a research note on Thursday, February 12th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Varex Imaging presently has an average rating of "Hold" and an average price target of $16.17.
View Our Latest Research Report on VREX
Institutional Investors Weigh In On Varex Imaging
Several hedge funds and other institutional investors have recently modified their holdings of the stock. State of Alaska Department of Revenue acquired a new position in Varex Imaging during the 3rd quarter valued at $27,000. Rockefeller Capital Management L.P. acquired a new stake in Varex Imaging in the 4th quarter worth $27,000. Quarry LP acquired a new stake in Varex Imaging in the 3rd quarter worth $64,000. Aquatic Capital Management LLC bought a new position in shares of Varex Imaging during the 3rd quarter worth about $117,000. Finally, Legato Capital Management LLC acquired a new position in shares of Varex Imaging during the third quarter valued at about $125,000.
Varex Imaging Company Profile
(
Get Free Report)
Varex Imaging Corporation is a global provider of X-ray imaging components and solutions for the medical, security and industrial markets. The company designs, develops and manufactures a broad range of products that convert X-ray energy into high-resolution digital images. Its portfolio includes X-ray tubes, flat panel detectors, digital sensors, specialty radiographic tubes and related software, all engineered to meet the demanding requirements of original equipment manufacturers (OEMs) in diagnostic imaging, computed tomography (CT), fluoroscopy, mammography, dental radiography and non-destructive testing applications.
The company's medical imaging offerings support a wide spectrum of clinical modalities, from portable radiography systems to advanced CT scanners, enhancing image quality and dose efficiency for healthcare providers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
